Update on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management

75Citations
Citations of this article
223Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the most severe cutaneous adverse reactions that are typically drug-induced in adults. Both SJS and TEN have high morbidity and mortality rates. SJS/TEN imposes clinical challenges for physicians managing patients suffering from this condition, both because it is rare and because it is a rapidly progressing systemic disease with severe cutaneous, mucosal, and systemic manifestations. Although many cases of SJS/TEN have been reported in the literature, there is no consensus regarding diagnostic criteria or treatment. Significant progress has been made in understanding its genetic predisposition and pathogenesis. This review is intended to provide physicians with a comprehensive but practical SJS/TEN roadmap to guide diagnosis and management. We review data on pathogenesis, reported precipitating factors, presentation, diagnosis, and management SJS/TEN focusing on what is new over the last 5 years.

Cite

CITATION STYLE

APA

Shah, H., Parisi, R., Mukherjee, E., Phillips, E. J., & Dodiuk-Gad, R. P. (2024, November 1). Update on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management. American Journal of Clinical Dermatology. Adis. https://doi.org/10.1007/s40257-024-00889-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free